Kidney function may change how VC005 drug works

NCT ID NCT07551570

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This early-stage study looks at how a single dose of VC005 tablets is processed in people with kidney impairment compared to those with normal kidney function. Researchers will measure drug levels in the blood and check safety. The goal is to understand if kidney problems affect how the drug behaves, which can guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
VC005 tablets
What this could lead to
If successful, this could help determine safe dosing of VC005 for people with kidney impairment.
What could go wrong
This is a very early Phase 1 study with only 32 people, so results may not apply broadly. It focuses on drug levels, not treatment effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Bengbu Medical University

    RECRUITING

    Bengbu, Anhui, 233000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.